LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

• DOI: 10.1016/j.annonc.2022.08.047
• Publication Date: 2022-09-13T22:34:00Z
• Authors: M. Tsuboi; Y-L. Wu; C. Grohe; T. John; M. Majem Tarruella; J. Wang; T. Kato; J.W. Goldman; S-W. Kim; C-J. Yu; H. Vinh Vu; G. Mukhametshina; C. Akewanlop; F. de Marinis; F.A. Shepherd; D. Urban; M. Stachowiak; A.L. Bolanos; X. Huang; R.S. Herbst
• Keywords: Osimertinib; T790M; Clinical endpoint